The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | HMA with venetoclax versus HMA alone in the frontline management of HR-MDS: a real-world analysis
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the findings of a retrospective real-world analysis comparing the outcomes of hypomethylating agent (HMA) therapy with or without venetoclax in the frontline management of higher-risk myelodysplastic syndromes (HR-MDS). Dr Murthy highlights that the combination of HMA and venetoclax led to significantly improved response rates, event-free survival (EFS), and overall survival (OS), with the most pronounced benefit seen in specific patient subgroups, including those with de novo MDS, no TP53 mutation, and baseline bone marrow blasts between 10% to 19%. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
